An Evernorth analysis estimates that biosimilar competition can deliver $225 billion to $375 billion in drug cost savings for plan sponsors by 2031. Learn strategies to capture these savings, while pr...
Christine Gilroy, MD, MSPH, September 25, 23Read More
We are taking a thoughtful and comprehensive approach to assessing biosimilar options that considers several factors.
July 24, 23Read More
July 10, 23Read More
By the end of 2023, 11 biosimilars for Humira will be available for patients living with inflammatory conditions, enabling lower costs for a drug class that currently represents nearly 25% of total dr...
June 30, 23Read More
During the closing session of the Evernorth Outcomes client event, panelists discussed the power of integrating pharmacy, medical, and behavioral care and looked ahead to explore the biggest opportuni...
May 05, 23Read More
Hybrid care models, affordability, health equity, and behavioral health emerge as top focus areas for plan sponsors and consumers.
Urvashi Patel, PhD, April 17, 23Read More